This content is from: Home

Extend IP terms for pharma, says report on new drugs

Policy makers should consider extending the term of IP protection offered to pharmaceutical products to encourage more research into new drugs, a new report has recommended

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial